Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Acetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR3 | O14843 | 1/20 | 0.35 |
| ▸ | LCK | P06239 | 1/20 | 0.35 |
| ▸ | FYN | P06241 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23355997 | 0.84 | — | — | |
| Phosphoric Acid SCHEMBL25335734 | 0.77 | — | — | |
| Acetic Acid SCHEMBL11542941 | 0.73 | FFAR3 (0.44) | FFAR3LCKFYN | |
| SCHEMBL26628369 | 0.72 | — | — | |
| SCHEMBL31036738 | 0.69 | — | — | |
| Acetic Acid SCHEMBL5150444 | 0.67 | FFAR3 (0.44) | FFAR3LCKFYN | |
| Acetic Acid SCHEMBL309352 | 0.66 | FFAR3 (0.50) | FFAR3LCKFYN | |
| Acetic Acid SCHEMBL10338273 | 0.66 | FFAR3 (0.50) | FFAR3LCKFYN | |
| Acetic Acid SCHEMBL813642 | 0.66 | FFAR3 (0.50) | FFAR3LCKFYN | |
| Acetic Acid SCHEMBL832778 | 0.66 | FFAR3 (0.50) | FFAR3LCKFYN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100069347-A1 | HETEROCYCLYL-SUBSTITUTED ANTI-HYPERCHOLESTEROLEMIC COMPOUNDS | MERCK SHARP & DOHME CORP. | 2010-03-18 | — | — | US | disclosed |
| US-20080280836-A1 | Anti-hypercholesterolemic biaryl azetidinone compounds | MORRIELLO GREGORI J | 2008-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280836-A1 | Anti-hypercholesterolemic biaryl azetidinone compounds | APOB, PCSK9, CYP46A1 | FFAR3 618/4885LCK 3923/4885FYN 1214/4885 |
| US-20100069347-A1 | HETEROCYCLYL-SUBSTITUTED ANTI-HYPERCHOLESTEROLEMIC COMPOUNDS | LDLR, PCSK9, CYP46A1 | FFAR3 984/4885LCK 4463/4885FYN 1579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.